Should You Buy CVS Health Stock Before Feb. 10?
Key Takeaways
- 1CVS Health has aggressively diversified into healthcare delivery through the $10.6 billion acquisition of Oak Street Health and the $8 billion deal for Signify Health.
- 2The stock’s valuation remains under pressure compared to historical averages due to rising medical loss ratios within the Aetna insurance division.
- 3CVS is implementing a massive restructuring plan, which includes closing approximately 900 retail stores by the end of 2024 to optimize its footprint and cut costs.
- 4Investors are closely monitoring the impact of Pharmacy Benefit Manager (PBM) transparency legislation, which poses a potential regulatory risk to the CVS Caremark business model.
- 5The company's 'CVS CostVantage' model aims to modernize pharmacy reimbursement, representing a shift toward more transparent, cost-plus pricing structures.
CVS Health (CVS) is currently navigating a complex transition from a retail pharmacy giant to an integrated healthcare provider, a strategy punctuated by its multi-billion dollar acquisitions of Signify Health and Oak Street Health. For investors considering a position before the February earnings window, the primary focus is on the company's Medical Benefit Ratio (MBR) and the performance of its Aetna insurance segment. Similar to its peer UnitedHealth (UNH), CVS has faced headwinds from rising medical utilization rates among seniors, which pressures profit margins. However, CVS trades at a significantly lower forward P/E multiple than the broader healthcare sector, suggesting a 'value' play if management can prove that higher utilization costs are stabilizing. The significance for investors lies in the sustainability of its dividend yield—currently near 4%—and its ability to offset retail pharmacy weakness (due to reimbursement pressures and store closures) with high-margin healthcare services. Watch for guidance regarding 2024 Medicare Advantage star ratings, as any downward revision in quality scores could significantly impact future federal bonus payments and earnings stability through 2025.